Abstract: Ductal eccrine carcinoma (DEC) is a rare sweat gland carcinoma with ductular differentiation. Clinically, it is characterized by a slowly growing, hardened plaque or nodule predominantly located on the head and neck. Histologically, DEC shares similar features to invasive breast carcinoma, thus causing great diagnostic challenges. We report a 69-year-old woman who presented with a hardened plaque on the axilla. A skin biopsy was performed and metastatic invasive breast carcinoma could not be ruled out. Complete excision and further workup were subsequently conducted, leading to the diagnosis of estrogen receptor positive DEC with associated axillary lymph node metastases. The patient received adjuvant radiotherapy to the left axilla and was started on oral letrozole. She is disease-free 14 months after initial diagnosis.
INTRODUCTION
Ductal eccrine carcinoma (DEC) is an extremely rare malignant adnexal tumor of eccrine origin. [1] [2] [3] It is more frequently located on the head and neck, but cases on the trunk and extremities have also been described. 4 Because of its striking histologic homology to invasive breast carcinoma, differential diagnosis can be challenging, particularly on unusual anatomic sites such as the breast or axilla.
2,5-7
We report a case of DEC of the axilla with associated axillary lymph node metastases.
CASE REPORT
A 69-year-old Caucasian woman presented with an asymptomatic hardened plaque on the left axilla that had been slowly growing for 2 years. It consisted of a well-demarked erythematous-violaceous plaque, measuring 26 x 11 mm, without an underlying palpable mass ( Figure 1 ). Both breasts were clinically normal.
An incisional skin biopsy was performed, and it showed dermal infiltration by small nests and ductal structures lined by atypical cuboidal epithelial cells embedded in a dense, desmoplastic stroma ( Figure 2 The patient received adjuvant radiotherapy at the left axilla (total dose 60 Gy), and started oral letrozole 2.5 mg daily. After 14 months of follow-up, she remains disease-free, under letrozole therapy.
DISCUSSION
Sweat gland carcinomas (SGC) are rare malignancies, accounting for <1% of all reported tumors. 5 Classification of these tumors is complex, due to the existence of a large number of rare entities, sometimes with overlapping features, and a multiplicity of terms used to designate the same neoplasms. 5, 8 To date, there is still no consensus regarding their nomenclature and classification. 5, 8 DEC, also reported as syringoid eccrine carcinoma, syringomatous carcinoma, eccrine epithelioma, malignant syringoma, and Clinically, DEC usually presents as a slowly growing, ill-defined, hardened nodule or plaque that can measure up to 10 cm.
It has a predilection for the head and neck, although cases on the trunk and extremities have also been described, and occurs mostly in middle-aged to elderly adults of both sexes. Because of its rarity, a standard method of treatment for DEC has not been established. 2, 5 Wide surgical excision is the treatment of choice for localized lesions. 1, 7 In metastatic disease, clinical benefit has been documented with both tamoxifen (in hormone receptor positive DEC) and a number of chemotherapy regimens, as well as radiotherapy. 5, 7, 10 Prophylactic lymph node excision should not be performed. 1 Regarding prognosis, there is conflicting data published in the literature. Some authors document a good prognosis and rare metastasis, while others report a poor prognosis, with up to 50% of patients developing metastasis to lymph nodes or viscera, and cases with visceral metastases being almost invariably fatal. 1, 3, 5, 9 Local recurrence is common and is seen in up to 70-80% of all cases. 1,2,7,8 q Ductal eccrine carcinoma of the axilla: a diagnostic pitfall
